deltatrials
Completed NA INTERVENTIONAL 2-arm NCT05647304

Pilot Clinical Investigation Evaluating the Safety and Performance of RGn550 in Treating Sportspeople Suffering From Acute Concussion Syndrome (RECOVERY)

Pilot Clinical Investigation Evaluating the Safety and Performance of RGn550 in Treating Sportspeople Suffering From Acute Concussion Syndrome - A Prospective, Comparative, Randomized, Simple-blinded, Monocentric Investigation [RGncon Investigation]

Sponsor: RCTs

Updated 6 times since 2023 Last updated: Feb 27, 2025 Started: Oct 11, 2022 Primary completion: Jun 20, 2023 Completion: Jun 20, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05647304, this NA trial focuses on Acute Concussion Syndrome and remains completed. Sponsored by RCTs, it has been updated 6 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2023 – ~Aug 2023 · 7 months · monthly snapshotRecruiting~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshotCompleted~Jan 2025 – ~Apr 2025 · 3 months · monthly snapshot~Apr 2025 – present · 17 months · monthly snapshotCompleted

Change History

6 versions recorded
  1. Apr 2025 — Present [monthly]

    Completed NA

  2. Jan 2025 — Apr 2025 [monthly]

    Completed NA

  3. Sep 2024 — Jan 2025 [monthly]

    Completed NA

  4. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  5. Aug 2023 — Jul 2024 [monthly]

    Completed NA

    Status: RecruitingCompleted

Show 1 earlier version
  1. Jan 2023 — Aug 2023 [monthly]

    Recruiting NA

    First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • RCTs
  • REGEnLIFE SAS
  • University Hospital, Montpellier
Data source: REGEnLIFE SAS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations